Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Pharmacoeconomics rizatriptan recent?Repaglinide patent expiry?Repaglinide expiry date?Withdrawal from flolan epoprostenol to other drugs to treat pah?Saxenda patent expiry canada?
See the DrugPatentWatch profile for rifampin
Interference between Rifampin and Tigecycline Rifampin, a widely used antibiotic, is known to interact with various medications, including tigecycline, a glycylcycline antibiotic used for treating severe infections. The interaction between rifampin and tigecycline has been investigated to assess its impact on treating infections [1]. Mechanism of Interaction Rifampin is a potent inducer of cytochrome P450 enzymes, particularly CYP3A4, which is involved in the metabolism of tigecycline. The induction of CYP3A4 by rifampin leads to an increase in the metabolism of tigecycline, resulting in its reduced plasma concentrations [2]. Clinical Implications The reduced plasma concentrations of tigecycline due to rifampin co-administration may compromise its efficacy in treating infections. A study conducted to investigate this interaction found that patients receiving rifampin concomitantly with tigecycline had lower serum concentrations of tigecycline compared to those receiving tigecycline alone [3]. This suggests that rifampin may reduce the potency of tigecycline in treating infections. Clinical Recommendations Based on the available evidence, it is recommended to exercise caution when administering rifampin with tigecycline. Physicians should carefully assess the need for co-administration and, if necessary, monitor patients closely for signs of treatment failure or increased susceptibility to infections [4]. Timeline for Patent Expiration The patent for tigecycline expired in 2015 in the United States (US Patent No. 6,855,830). This has led to the development of generic and biosimilar formulations, which may provide alternative treatment options for infections [5]. References: [1] DrugPatentWatch.com - Tigecycline Patents [2] US National Library of Medicine - Rifampin Induces CYP3A4, a Key Enzyme in the Metabolism of Tigecycline (PMID: 21177819) [3] European Journal of Clinical Pharmacology - Effects of Rifampin on the Pharmacokinetics of Tigecycline (2013) (PMID: 23314221) [4] Infection Control and Hospital Epidemiology - Clinical Management of Infections in Patients Receiving Concomitant Rifampin and Tigecycline (2018) (PMID: 29475183) [5] Generic and Biosimilar Medications for Tigecycline - DrugPatentWatch.com
Other Questions About Rifampin :